Thursday, October 24, 2013

Now Japan pulls Gardasil shots for young girls

Now Japan pulls Gardasil shots for young girls
Nearly 2,000 'adverse events' reported from cervical cancer vaccine
The organization continued, “The U.S. government has taken the opposite approach amid equally alarming cases of serious side effects. Not only does the Obama administration continue recommending the vaccine (Gardasil), it spends large sums of taxpayer dollars promoting it and works hard to keep details involving its dangers secret.”

Multiple reports uncovered and cited by Judicial Watch discuss the dangers – including death – that the drug presents to children who are given the injections, which cost $600 per patient.

Other side effects have included seizures, blindness, paralysis, speech problems, pancreatitis, and short-term memory loss.

“Incredibly, the Food and Drug Administration (FDA) fast-tracked Gardasil’s approval and the Centers for Disease Control and Prevention (CDC) recommends it for girls starting at age 9,” Judicial Watch has confirmed.

Gardasil
Gardasil (Merck & Co.), also known as Gardisil or Silgard,[1][2] is a vaccine for use in the prevention of certain types of human papillomavirus (HPV),[3] specifically HPV types 6, 11, 16 and 18.[4][5] HPV types 16 and 18 cause an estimated 70% of cervical cancers,[6][7] and are responsible for most HPV-induced anal,[8] vulvar, vaginal,[9] and penile cancer cases. HPV types 6 and 11 cause an estimated 90% of genital warts cases.

Merck
Akin, Gump, Strauss, Hauer & Feld, LLP was the lobby firm for Merck.

Note: James F. Collins was a senior advisor for Akin, Gump, Strauss, Hauer & Feld, LLP, and is a senior associate at the Carnegie Endowment for International Peace (think tank).
Jessica Tuchman Mathews is the president of the Carnegie Endowment for International Peace (think tank), a director at the Nuclear Threat Initiative (think tank), a director at the American Friends of Bilderberg (think tank), was an honorary trustee at the Brookings Institution (think tank), and a 2008 Bilderberg conference participant (think tank).
Ed Griffin’s interview with Norman Dodd in 1982
(The investigation into the Carnegie Endowment for International Peace uncovered the plans for population control by involving the United States in war)
Foundation to Promote Open Society was a funder for the Carnegie Endowment for International Peace (think tank), the Millennium Promise, the Human Rights Watch, and the Brookings Institution (think tank).
George Soros is the chairman for the Foundation to Promote Open Society, and was a benefactor for the Human Rights Watch.
Amy L. Robbins is a director at the Millennium Promise, a director at the Human Rights Watch, and a board member for the CDC Foundation.
CDC Foundation is a foundation for the Centers for Disease Control and Prevention (CDC).
Carnegie Endowment for International Peace (think tank) was a funder for the Nuclear Threat Initiative (think tank).
Donald Kennedy was a trustee at the Carnegie Endowment for International Peace (think tank), and a commissioner for the U.S. Food and Drug Administration (FDA).
Margaret A. Hamburg is a VP at the Nuclear Threat Initiative (think tank), and a commissioner for the U.S. Food and Drug Administration (FDA).
Mark B. McClellan was a commissioner for the U.S. Food and Drug Administration (FDA), and a senior fellow at the Brookings Institution (think tank).
Cyrus F. Freidheim Jr. is an honorary trustee at the Brookings Institution (think tank), and a member of the Commercial Club of Chicago.
Valerie B. Jarrett is a member of the Commercial Club of Chicago, the senior adviser for the Barack Obama administration, and her great uncle is Vernon E. Jordan Jr.
Vernon E. Jordan Jr. is Valerie B. Jarrett’s great uncle, an honorary trustee at the Brookings Institution (think tank), a senior counsel for Akin, Gump, Strauss, Hauer & Feld, LLP, a director at the American Friends of Bilderberg (think tank), and a 2008 Bilderberg conference participant (think tank).
Akin, Gump, Strauss, Hauer & Feld, LLP was the lobby firm for Merck.

No comments: